Blood test could track brain cancer treatment

NCT ID NCT06610682

Recruiting now Knowledge-focused Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

Summary

This study is testing whether tiny pieces of tumor DNA (ctDNA) found in blood and spinal fluid can be used to monitor a specific type of brain tumor. Fifteen adults with recurrent BRAF-V600E mutant glioma will take an experimental drug (plixorafenib). Researchers will check if changes in ctDNA levels match how the tumor responds on MRI scans, aiming to find a less invasive way to track treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600E MUTATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Johns Hopkins
RECRUITING

Baltimore, Maryland, 21231, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BRAF V600E MUTATION